Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) EBITDA (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed EBITDA for 6 consecutive years, with -$6.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 58.6% to -$6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33.5 million through Dec 2025, up 46.88% year-over-year, with the annual reading at -$33.5 million for FY2025, 46.88% up from the prior year.
  • EBITDA hit -$6.6 million in Q4 2025 for Bolt Biotherapeutics, up from -$7.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$6.6 million in Q4 2025 to a low of -$27.4 million in Q4 2021.
  • Historically, EBITDA has averaged -$17.6 million across 5 years, with a median of -$17.9 million in 2023.
  • Biggest five-year swings in EBITDA: tumbled 183.67% in 2021 and later soared 59.41% in 2025.
  • Year by year, EBITDA stood at -$27.4 million in 2021, then soared by 30.0% to -$19.2 million in 2022, then increased by 7.89% to -$17.7 million in 2023, then rose by 9.31% to -$16.0 million in 2024, then skyrocketed by 58.6% to -$6.6 million in 2025.
  • Business Quant data shows EBITDA for BOLT at -$6.6 million in Q4 2025, -$7.1 million in Q3 2025, and -$8.6 million in Q2 2025.